Canaccord raised the firm’s price target on Natera (NTRA) to $165 from $150 and keeps a Buy rating on the shares. The firm remains “highly bullish” on Natera after “another standout quarter” and guidance raise. The company’s performance was primarily driven by solid increases in test volume and average selling price in Women’s Health and Oncology, the analyst tells investors in a research note. Canaccord believes Natera remains undervalued, saying the shares offer attractive upside potential.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- Natera Reports Strong Revenue Growth in Q3 2024
- Closing Bell Movers: Instacart down 6% after earnings
- Natera reports Q3 EPS (26c), consensus (57c)
- Natera raises FY24 revenue view to $1.61B-$1.64B from $1.49B-$1.52B
- Natera jumps 9% to $146.94 after Q3 results, raised FY24 guidance
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
